Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
A Piccardo, M Puntoni, G Ferrarazzo, L Foppiani… - European journal of …, 2018 - Springer
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …
[HTML][HTML] Is very high thyroid stimulating hormone level required in differentiated thyroid cancer for ablation success?
Z Hasbek, B Turgut - Molecular imaging and radionuclide therapy, 2016 - ncbi.nlm.nih.gov
Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …
A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma …
J Xiao, C Yun, J Cao, S Ding, C Shao, L Wang… - Scientific Reports, 2021 - nature.com
Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for
initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma …
initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma …
Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
H Fu, C Ma, L Tang, F Wu, B Liu… - The Quarterly Journal of …, 2014 - europepmc.org
Aim We aim to assess the effects of recombinant human thyrotropin (rhTSH) versus thyroid
hormone withdrawal (THW), and rhTSH-aided low doses (1.11 GBq and 1.85 GBq) versus …
hormone withdrawal (THW), and rhTSH-aided low doses (1.11 GBq and 1.85 GBq) versus …
A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist?
L Giovanella, A Piccardo - European Journal of Nuclear Medicine and …, 2016 - Springer
A growing body of evidence supported the possibility to prepare patients affected by
differentiated thyroid cancer (DTC) at low and/or intermediate risk with recombinant human …
differentiated thyroid cancer (DTC) at low and/or intermediate risk with recombinant human …
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk …
M Chianelli, V Todino, FM Graziano… - European Journal of …, 2009 - academic.oup.com
Objective (a) To compare the efficacy of low-activity (2 GBq; 54 mCi) 131I ablation using l-
thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid …
thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid …
TSH≥ 30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer
N Ju, L Hou, H Song, Z Qiu, Y Wang… - European Thyroid …, 2023 - etj.bioscientifica.com
Purpose To determine whether thyroid-stimulating hormone level≥ 30 mU/L is necessary
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …
Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low‐risk well‐differentiated thyroid cancer
S Tsirona, V Vlassopoulou, M Tzanela… - Clinical …, 2014 - Wiley Online Library
Objective Postoperative radioiodine remnant ablation (RRA) represents an adjunctive
therapeutic modality in patients with differentiated thyroid cancer (DTC). The impact of late …
therapeutic modality in patients with differentiated thyroid cancer (DTC). The impact of late …
Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma
Objectives Radioiodine can be applied for remnant ablation in low and low to intermediate-
risk patients with differentiated thyroid cancer (DTC). A controversy still exists about the …
risk patients with differentiated thyroid cancer (DTC). A controversy still exists about the …
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario
A Campennì, L Giovanella, SA Pignata… - Nuclear Medicine …, 2015 - journals.lww.com
Objective Differentiated thyroid cancer is rare, but the incidence has been increasing in the
last few decades. Early treatment is based on surgery and thyroid remnant ablation (TRA) by …
last few decades. Early treatment is based on surgery and thyroid remnant ablation (TRA) by …